Construction of a predictive model for gastric cancer neuroaggression and clinical validation analysis: A single-center retrospective study

Table 1 Clinical data analysis of 80 gastric cancer patients, n (%)

Project	PNI positive group (n = 54)	PNI negative group (n = 26)	T/χ2/Z	P value
Age (years, mean ± SD)	65.00 ± 8.75	66.76 ± 4.82	-0.823	0.416
Sex			4.786	0.029
Male	42 (78)	14 (54)
Female	12 (22)	12 (46)
Alpha fetoprotein, ng/mL	2.980 (2.160, 3.650)	2.590 (1.700, 3.780)	0.578	0.568
Carcinoembryonic antigen (ng/mL)	56.735 ± 268.309	2.109 ± 1.085	0.729	0.470
CA125 (U/mL, mean ± SD)	124.600 ± 540.554	9.191 ± 4.435	0.765	0.449
CA199 [U/mL, M (Q1, Q3)]	16.485 (11.890, 36.635)	6.77 (3.260, 16.335)	3.133	0.001
Tumor thickness (mm, mean ± SD)	20.149 ± 6.410	14.746 ± 5.065	2.664	0.011
Lauren typing			15.949	0.000
Intestinal type	16 (30)	20 (77)
Diffuse type	16 (30)	2 (8)
Mixed type	22 (40)	4 (15)
Borrmann classification			13.219	0.004
I	2 (3)	2 (7)
Ⅱ	8 (15)	12 (47)
Ⅲ	34 (63)	6 (23)
IV	10 (19)	6 (23)
Differentiation degree			2.825	0.244
High	10 (19)	2 (8)
Middle	18 (33)	8 (31)
Low	26 (48)	16 (61)

CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199; M: Median.